Browsing by Author "Ugurlu, I"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment
    Çakir, E; Saydan, D; Gülbagci, B; Özen, M; Ugurlu, I; Demirci, A; Bilir, F; Hacibekiroglu, I; Yildiz, N; Akcali, S; Altindis, M; Varim, C; Yaylaci, S; Bilir, C
    - OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immuni-ty in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sino-vac-CoronaVac COVID-19 vaccine immunogenici-ty and compared it with natural COVID-19 disease in cancer patients during their cancer therapy.PATIENTS AND METHODS: A total of 111 pa-tients with cancer and who are on active treat-ment were included in the study. This is a sin-gle-center study and was designed prospec-tively. Two group of patients were included in the study, natural disease and vaccinated group.RESULTS: A total of 111 patients were in-cluded in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while af-ter the second dose of vaccine were 2.6 (1.0-7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immu-notehrapy/targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference be-tween the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively].CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving ac-tive systemic therapy. On the other hand, nat-ural disease immunogenicity was higher than vaccinated group.
  • No Thumbnail Available
    Item
    Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
    Beypinar, I; Demir, H; Yaslikaya, S; Köseci, T; Demir, B; Çolak, G; Agaoglu, AB; Sahbazlar, M; Sanci, PC; Cabuk, D; Isik, U; Sahin, E; Coskun, A; Caner, B; Aykut, T; Artac, M; Duygulu, ME; Sever, N; Öksüz, S; Turan, N; Aykan, MB; Tüzün, EK; Uysal, M; Ugurlu, I; Sakin, A; Acar, C; Özaskin, D; Sakalar, T; Keskinkilic, M; Yavuzsen, T; Köse, N; Ertürk, I; Yildirim, N; Balçik, OY; Alkan, A; Selvi, O; Ercin, E; Ünal, OU; Karaçin, C
    Purpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.